Scientific article

Interleukin-1 blockade in refractory giant cell arteritis

Published inJoint bone spine, vol. 81, no. 1, p. 76-78
Publication date2014

Giant cell arteritis is a primary large-vessel vasculitis characterized by an arterial wall inflammation associated with intimal hyperplasia leading to arterial occlusion. Glucocorticoids remain the mainstay of giant cell arteritis treatment. However, relapses and glucocorticoid-related complications are frequent and therapeutic options for refractory giant cell arteritis are quite limited. Like tumor necrosis factor-α and interleukin-6, interleukin-1β is also highly expressed in inflamed arterial walls of patients with giant cell arteritis and may contribute in the pathogenesis of this disease. We report treatment of three cases of refractory giant cell arteritis successfully treated with anakinra, an interleukin-1 blockade therapy. Anakinra was effective for all patients, yielding improvement in their inflammation biomarkers and/or in their symptoms, as well as a disappearance of arterial inflammation in PET/CT for two of them.

  • Aged
  • Aged, 80 and over
  • Antirheumatic Agents/therapeutic use
  • Female
  • Giant Cell Arteritis/drug therapy/radionuclide imaging
  • Glucocorticoids/therapeutic use
  • Humans
  • Interleukin 1 Receptor Antagonist Protein/therapeutic use
  • Interleukin-1/antagonists & inhibitors
  • Male
  • Positron-Emission Tomography
Affiliation Not a UNIGE publication
Citation (ISO format)
LY, Kim-Heang et al. Interleukin-1 blockade in refractory giant cell arteritis. In: Joint bone spine, 2014, vol. 81, n° 1, p. 76–78. doi: 10.1016/j.jbspin.2013.06.004
Main files (1)
Article (Published version)
ISSN of the journal1297-319X

Technical informations

Creation11/07/2015 2:52:00 PM
First validation11/07/2015 2:52:00 PM
Update time03/14/2023 11:57:24 PM
Status update03/14/2023 11:57:23 PM
Last indexation01/16/2024 7:47:13 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack